What is Sanara MedTech Inc.'s market cap?

Sanara MedTech Inc. (SMTI) has a market capitalization of $236.9M and trades on NASDAQ.

What is Sanara MedTech Inc.'s revenue and profitability?

Sanara MedTech Inc. generated $107.5M in trailing twelve-month revenue with a net loss of $33.6M, representing a net margin of -31.2%. Gross margin stands at 92.9%, with free cash flow of -$3.8M. These figures are based on the Q1 2026 filing.

Who are Sanara MedTech Inc.'s competitors?

Sanara MedTech Inc.'s key competitors include Integra LifeSciences Holdings Corporation, Becton Dickinson and Company, Solventum, and others. These companies compete in similar markets and product categories.

Who does Sanara MedTech Inc. partner with?

Sanara MedTech Inc.'s notable partners include Biomimetic Innovations Limited, Tufts University.

What subsidiaries does Sanara MedTech Inc. have?

Sanara MedTech Inc.'s subsidiaries include Rochal Technologies, Sanara Collagen Peptides, LLC.

Where is Sanara MedTech Inc. headquartered?

Sanara MedTech Inc. is headquartered in United States of America and employs approximately 108 people. It has been publicly traded since 2020.

Sanara MedTech Inc.

SMTI

Sanara MedTech is a medical technology company that develops and commercializes transformative surgical solutions designed to improve clinical outcomes and reduce healthcare expenditures.

Market cap

$236.89M+6.2%

Revenue$107.5M+17.4%

Net income-$33.6M-194%

Free cash flow-$3.8M+36.7%

EPS (diluted)-$3.90-191%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$27.8MBeat by $998.5K EPS$0.04Beat by $0.17

Read the full report

Next report

Aug 12, 2026 (In 2 weeks)

Revenue estimate$28.5M

EPS estimate-$0.07

Financials

Q1 2026

Income statement

See full

Revenue$27.8M+18.6%

Gross profit$25.9M+19.8%

Operating income$2.6M+221%

Net income$459.0K+113%

EPS (diluted)$0.05+112%

Balance sheet

See full

Cash & equivalents$13.6M-34.3%

Total debt$48.4M+8.2%

Total equity$7.0M-80.8%

Total assets$69.3M-28.1%

Cash flow

See full

Operating cash flow-$2.5M-23.3%

CapEx$43.8K-97.5%

Free cash flow-$2.5M+32.6%

Valuation & ratios

Valuation

See full

Market cap$236.89M+6.2%

Enterprise value$271.66M+8.3%

P/S2.2×-0.1×

Profitability

See full

Gross margin92.9%+1.8pp

Operating margin6.1%+5.1pp

Net margin-31.2%-93.4pp

Returns & leverage

See full

Return on equity-153.7%-199pp

Debt / equity6.9×+5.7×

Current ratio2.3×-0.5×

Segments

By product

See full

Soft Tissue Repair Products$24.9M+21.5%

Bone Fusion Products$2.9M-1.6%

Competitors

By market cap

Stryker$129.09B-15.7%

Becton, Dickinson and Company$43.8B-16.5%

Solventum$13.9B+9.2%

Globus Medical$10.6B+44.5%

IAR

Integra LifeSciences$1.5B+49.2%

Orthofix Medical Inc.$481.0M+7.7%

Sanara MedTech Inc.$236.9M+6.5%

Xtant Medical Holdings$61.7M-29.7%

By revenue growth

Globus Medical+23.5%

Sanara MedTech Inc.+17.4%

Stryker+8.8%

Becton, Dickinson and Company+6.4%

Orthofix Medical Inc.+2.6%

IAR

Integra LifeSciences+1.6%

Xtant Medical Holdings-0.3%

Solventum-0.5%

By net margin

Globus Medical18.92%+11.5pp

Solventum17.33%+12.8pp

Stryker13.21%+0.9pp

Becton, Dickinson and Company5.33%-2.1pp

Xtant Medical Holdings1.5%+11.3pp

IAR

Integra LifeSciences-0.44%+32.4pp

Orthofix Medical Inc.-7.27%+10.5pp

Sanara MedTech Inc.-31.23%-18.8pp

Profile

Sanara MedTech is a medical technology company that develops and commercializes transformative surgical solutions designed to improve clinical outcomes and reduce healthcare expenditures. The company primarily focuses on the U.S. surgical market, offering a portfolio of advanced soft tissue repair and bone fusion products used in operating rooms and sterile environments. Its core value proposition centers on the 'Prepare, Promote and Protect' strategy, providing evidence-based tools that support the body's natural healing process while reducing costly complications like infections and readmissions.

Competitive position

Sanara positions itself as an innovation-led provider of bioactive surgical solutions that offer a dominant cost-effectiveness profile compared to standard care.

GeographiesUnited States

Customer segmentsAcute Care Facilities, Surgical Centers, Specialized Surgeons

Business modelDirect Sales, Distributor Network, Research and Development

SuppliersContract Manufacturers, Third-party R&D partners, Human tissue suppliers (allografts), Bovine collagen suppliers

CustomersHospital Value Analysis Committees, Surgical specialty distributors, Inpatient and outpatient surgical facilities

CountryUnited States of America

Listed2020

Employees108.0

CEOSeth D. Yon

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitesanaramedtech.com

FilingsSEC EDGAR

Ask your AI about Sanara MedTech Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sanara MedTech Inc.'s market cap?: Sanara MedTech Inc. (SMTI) has a market capitalization of $236.9M and trades on NASDAQ.
What is Sanara MedTech Inc.'s revenue and profitability?: Sanara MedTech Inc. generated $107.5M in trailing twelve-month revenue with a net loss of $33.6M, representing a net margin of -31.2%. Gross margin stands at 92.9%, with free cash flow of -$3.8M. These figures are based on the Q1 2026 filing.
Who are Sanara MedTech Inc.'s competitors?: Sanara MedTech Inc.'s key competitors include Integra LifeSciences Holdings Corporation, Becton Dickinson and Company, Solventum, and others. These companies compete in similar markets and product categories.
Who does Sanara MedTech Inc. partner with?: Sanara MedTech Inc.'s notable partners include Biomimetic Innovations Limited, Tufts University.
What subsidiaries does Sanara MedTech Inc. have?: Sanara MedTech Inc.'s subsidiaries include Rochal Technologies, Sanara Collagen Peptides, LLC.
Where is Sanara MedTech Inc. headquartered?: Sanara MedTech Inc. is headquartered in United States of America and employs approximately 108 people. It has been publicly traded since 2020.